Advances in medical therapy of thyroid-associated ophthalmopathy

References

• Prummel M F, Wiersinga W M, Mourits M P, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 1990; 150: 1098–1101
   PubMedGoogle Scholar
• Prummel M F, Wiersinga W M, Mourits M P, Koornneef L, Berghout A, van der Gaag R. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol 1989; 121(Suppl 2)185–189
   PubMedGoogle Scholar
• Brain R, Aterman K, Cope C L, Dunlop D M, Fraser T R, Greene R, et al. Cortisone in exophthalmos. Report on a therapeutic trial of cortisone and corticotropin in exophthalmic ophthalmoplegia by a panel appointed by the medical research council. Lancet 1955; 1: 6–9
   Google Scholar
• Brown J, Coburn J W, Wigod R A, Hiss J M, Dowling J T. Adrenal steroid therapy of severe infiltrative ophthalmopathy of Graves' disease. Am J Med 1963; 34: 786–794
   PubMed Web of Science ®Google Scholar
• Day R M, Carroll F D. Corticosteroids in the treatment of optic nerve involvement associated with thyroid dysfunction. Arch Ophthalmol 1968; 79: 279–282
   PubMedGoogle Scholar
• Apers R CL, Oosterhuis J A, Goslings B M, Bierlaagh J JM. Prednisone treatment in endocrine ophthalmopathy. Mod Probl Ophthalmol 1975; 14: 414–420
   PubMedGoogle Scholar
• Bartalena L, Marcocci C, Chiovato L, Lepri A, Andreani D, Cavallacci G, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metabol 1983; 56: 1139–1144
   PubMed Web of Science ®Google Scholar
• Wiersinga W M, Smit T, Schuster-Uttenhoeve A LJ, van der Gaag R, Koornneef L. Therapeutic outcome of prednisone medication and the orbital irradiation in patients with Graves' ophthalmopathy. Ophthalmologica 1988; 197: 75–84
   PubMedGoogle Scholar
• Prummel M F, Mourits M P, Berghout A, Krenning E P, van der Gaag R, Koornneef L, Wiersinga W M. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989; 321: 1353–1359
   PubMed Web of Science ®Google Scholar
• Prummel M F, Mounts M Ph, Blank L, Berghout A, Koomneef L, Wiersinga W M. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342: 949–954
   PubMed Web of Science ®Google Scholar
• Teng C S, Crombie A L, Hall R, Ross W M. An evaluation of supervoltage orbital irradiation for Graves' ophthalmopathy. Clin Endocrinol 1980; 13: 545–551
   PubMed Web of Science ®Google Scholar
• Hurbli T, Char D H, Harris J, Weaver K, Greenspan F, Sheline G. Radiation therapy for thyroid eye disease. Am J Ophthalmol 1985; 99: 633–637
   PubMed Web of Science ®Google Scholar
• Olivotto I A, Ludgate C M, Allen L H, Rootman J. Supervoltage radiotherapy for Graves' ophthalmopathy: CCABC technique and results. Int Radiation Oncol Biol Phys 1985; 11: 2085–2090
   PubMed Web of Science ®Google Scholar
• Konishi J, Iida Y, Kasagi K, Misaki T, Arai K, Endo K, et al. Clinical evaluation of radiotherapy for Graves' ophthalmopathy. Endocrinol Jpn 1986; 33: 637–644
   PubMedGoogle Scholar
• Palmer D, Greenberg P, Cornwell P, Parker R G. Radiation therapy for Graves' ophthalmopathy: a retrospective analysis. Int J Radiat Oncol Biol Phys 1987; 13: 1815–1820
   PubMed Web of Science ®Google Scholar
• Pigeon P, Orgiazzi J, Berthezene F, Gerard J P, Haguenauer J P, Mornex R. High voltage orbital radiotherapy, surgical orbital decompression in the management of Graves' ophthalmopathy. Horm Res 1987; 26: 172–176
   PubMedGoogle Scholar
• Sandier H M, Rubenstein J H, Fowble B L, Sergott R C, Savino P J, Bosley T M. Results of radiotherapy for thyroid ophthalmopathy. Int J Radiation Oncol Biol Phys 1989; 17: 823–827
   PubMedGoogle Scholar
• Lloyd W C, Leone C R. Supervoltage orbital radiotherapy in 36 cases of Graves' disease. Am J Ophthalmol 1992; 113: 374–380
   PubMedGoogle Scholar
• Kinyoun J L, Kalina R E, Brower S A, Mills R P, Johnson R H. Radiation retinopathy following orbital irradiation for Graves' ophthalmopathy. Arch Ophthalmol 1984; 102: 1473–1476
   PubMedGoogle Scholar
• Polak B CP, Wijngaarde R. Radiation retinopathy in patients with both diabetes mellitus and ophthalmic Graves' disease. Orbit 1995; 14: 71–74
   Google Scholar
• Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W, et al. Ciclosporin and prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized, prospective study. Eur J Clin Invest 1986; 16: 415–422
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Izumi M, Kiriyama T, Yokoyama N, Morita S, Kakezono F, Ohtakara S. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol 1987; 116: 513–518
   PubMedGoogle Scholar
• Hiromatsu Y, Tanaka K, Sato M, et al. Intravenous methylprednisolone pulse therapy for Graves' ophthalmopathy. Endocr J 1993; 40: 63–72
   PubMedGoogle Scholar
• Kendall-Taylor P, Crombie A L, Stephenson A M, Hardwick M, Hall K. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. Br Med J 1988; 297: 1574–1578
   PubMedGoogle Scholar
• Guy J R, Fagien S, Donovan J P, Rubin M L. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 1989; 96: 1048–1053
   PubMed Web of Science ®Google Scholar
• Baethge B A, Lidsky M D, Goldberg J W. A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Ann Pharmacotherapy 1992; 26: 316–320
   PubMedGoogle Scholar
• Dwyer J. Manipulating the immune system with immune globulin. New Engl J Med 1992; 326: 107–116
   PubMed Web of Science ®Google Scholar
• Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immuno-globulin treatment in Graves' ophthalmopathy. Acta Endocrinol 1992; 126: 13–23
   PubMedGoogle Scholar
• Chang T C, Kao S CS, Huang K M. Octreotide and Graves' ophthalmopathy and pretibial myxedema. Br Med J 1992; 304: 158
   PubMed Web of Science ®Google Scholar
• Krassas G E, Dumas A, Pontikides N, Kaltsas Th. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol 1995; 42: 571–580
   PubMed Web of Science ®Google Scholar
• Rundle F F, Wilson C W. Development, course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy. Clin Sci 1945; 5: 177–194
   PubMed Web of Science ®Google Scholar
• Hales I B, Rundle F F. Ocular changes in Graves' disease. A long-term follow-up study. Q J Med 1960; 29: 113–126
   PubMedGoogle Scholar
• Mourits M P, Koornneef L, Wiersinga W M, Prummel M F, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73: 639–644
   PubMed Web of Science ®Google Scholar
• Mourits M Ph, Koornneef L, Wiersinga W M, van der Gaag R. Prospective evaluation of the clinical activity score as predictor of therapeutic outcome after immunosuppressive treatment of Graves' ophthalmopathy (abstract). Thyroid 1991, Suppl 1: 5–9
   Google Scholar
• Postema P TE, Krenning E P, Wijngaarde R, et al. ‘111Tn-DTPA-D-Phe1’ octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?. J Clin Endocrinol Metabol 1994; 79: 1845–1851
   PubMedGoogle Scholar
• Just M, Kahaly G, Higer H P, Rosier H P, Kutzner J, Beyer J, Thelen M. Graves' ophthalmopathy: role of MR imaging in radiation therapy. Radiology 1991; 179: 187–190
   PubMed Web of Science ®Google Scholar
• Hiromatsu Y, Kojima K, Ishisaka N, et al. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosup-pressive therapy. Thyroid 1992; 2: 299–305
   PubMedGoogle Scholar
• Kahaly G, Schuler M, Sewell A C, Bernhard G, Beyer J, Krause U. Urinary glycosaminoglycans in Graves' ophthalmopathy. Clin Endocrinol 1990; 33: 35–44
   PubMed Web of Science ®Google Scholar
• Martinez-Brü C, Ampredia X, Castrillo P, Gonzalez-Sartre F. Urinary glycosaminoglycans in active Graves' ophthalmopathy. Clin Chem 1992; 38: 2341
   PubMedGoogle Scholar